Takeda Pharmaceutical Co. will voluntarily recall the Omontys anemia drug in the United States in response to reports of fatal reactions in some patients.
Omontys is used to treat anemia caused by chronic kidney diseases. In the U.S. market, Takeda has been selling it jointly with domestic drugmaker Affymax Inc.
Since the U.S. launch of the drug in April 2012, it was administered to about 25,000 patients, of whom 0.2 percent showed hypersensitivity reactions.
Fatal reactions were reported in about 0.02 percent, according to Takeda.
The two companies have asked health care professionals to stop prescribing the drug.
Takeda said the recall will not affect its current group earnings projections for fiscal 2012, which ends next month.